Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?

doi:10.5497/wjp.v3.i4.72

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12863)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

976

WORD

354

HTML

8669

Figures (1-4)

459

Tables (1-1)

155

Sum=10613

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1102

Download

1148

Sum=2250

Dec 9, 2014 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Dec 9, 2014; 3(4): 72-85
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.72

Full Size Figure Download Figure

Figure 1 Characteristic features of ErbB receptors family. A: Schematic representation of HER1 and HER4 conformational change upon ligand interaction; B: Schematic representation of HER2 heterodimers. HER: Human epidermal growth factor receptor 2; ErbB: erythroblastic leukemia viral oncogene homolog.

Citation: Mazzucchelli S, Truffi M, Fiandra L, Sorrentino L, Corsi F. Targeted approaches for HER2 breast cancer therapy: News from nanomedicine? World J Pharmacol 2014; 3(4): 72-85
URL: https://www.wjgnet.com/2220-3192/full/v3/i4/72.htm
DOI: https://dx.doi.org/10.5497/wjp.v3.i4.72